Stay updated on IP Nivolumab Tolerance in Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the IP Nivolumab Tolerance in Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the IP Nivolumab Tolerance in Ovarian Cancer Clinical Trial page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    6 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 'Home Search Results Study Record' to 'Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Ovarian Carcinoma (ICONIC)'. This change likely represents an update related to a clinical trial study on the tolerance of intraperitoneal nivolumab in patients with advanced ovarian carcinoma after debulking surgery and HIPEC.
    Difference
    100%
    Check dated 2024-05-13T00:47:22.000Z thumbnail image
  7. Check
    7 days ago
    Change Detected
    Summary
    The value provided by Hospices Civils de Lyon for the information on the webpage has recently changed.
    Difference
    73%
    Check dated 2024-05-11T19:39:53.000Z thumbnail image
  8. Check
    18 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:54:58.000Z thumbnail image

Stay in the know with updates to IP Nivolumab Tolerance in Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the IP Nivolumab Tolerance in Ovarian Cancer Clinical Trial page.